Heart & Lung: The Journal of Acute and Critical Care
Volume 36, Issue 3 , Pages 195-204 , May 2007

Efficacy of N-acetylcysteine and hydration versus placebo and hydration in decreasing contrast-induced renal dysfunction in patients undergoing coronary angiography with or without concomitant percutaneous coronary intervention

  • Rajamalar A. Seyon, RN, MN, CCN (C)

      Affiliations

    • Department of Cardiology, Royal Alexandra Hospital, Edmonton, Alberta, Canada
    • Faculty of Nursing, University of Alberta, Edmonton, Alberta, Canada
    • ,
  • Louise A. Jensen, RN, PhD

      Affiliations

    • Faculty of Nursing, University of Alberta, Edmonton, Alberta, Canada
    • Corresponding Author InformationReprint requests: Louise A. Jensen, RN, PhD, University of Alberta, 4-112D Clinical Sciences Building, Edmonton, Alberta, Canada.
    • ,
  • Ian A. Ferguson, MD, FRCP (C)

      Affiliations

    • Internal Medicine, Nephrology, Royal Alexandra Hospital, Edmonton, Alberta, Canada
    • ,
  • Randall G. Williams, MD, FRCP (C)

      Affiliations

    • Faculty of Medicine, University of Alberta, Edmonton, Alberta, Canada
    • Coronary Care Unit, Royal Alexandra Hospital, Edmonton, Alberta, Canada.

References 

  1. American Heart Association. 2002 Heart and stroke statistical update. Dallas, TX: American Heart Association; 2001;
  2. Scanlon PJ, Faxon DP, Audet AM, et al. ACC/AHA guidelines for coronary angiography: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Coronary Angiography). J Am Coll Cardiol. 1999;33:1756–1824
  3. Spinler SA, Goldfarb S. Nephrotoxicity of contrast media following cardiac angiography: pathogenesis, clinical course, and preventive measures, including the role of low-osmolality contrast media. Ann Pharmacother. 1992;26(1):56–64
  4. Deray G, Jacobs C. Radiocontrast nephrotoxicity: a review. Invest Radiol. 1995;30(4):221–225
  5. Morcos SK, Thomsen HS, Webb JAW Contrast Media Safety Committee of the European Society of Urogenital Radiology. Contrast-media-induced nephrotoxicity: a consensus report. Eur Radiol. 1999;9:1602–1613
  6. Quader MA, Sawmiller C, Sumpio BA. Contrast-induced nephropathy: review of incidence and pathophysiology. Ann Vasc Surg. 1998;12(6):612–620
  7. Tommaso CL. Contrast-induced nephrotoxicity in patients undergoing cardiac catheterization. Cathet Cardiovasc Diagn. 1994;31:316–321
  8. Davidson CJ, Hlatky M, Morris KG, et al. Cardiovascular and renal toxicity of a nonionic radiographic contrast agent after cardiac catheterization. Ann Intern Med. 1989;110(2):119–124
  9. Taliercio CP, McCallister SH, Holmes DR, Ilstrup DM, Vlietstra RE. Nephrotoxicity of non-ionic contrast media after cardiac angiography. Am J Cardiol. 1989;64(12):815–816
  10. Abizaid AS, Clark CE, Mintz GS, et al. Effects of dopamine and aminophylline on contrast-induced acute renal failure after coronary angioplasty in patients with pre-existing renal insufficiency. Am J Cardiol. 1999;83:260–263
  11. Martin-Paredero V, Dixon SM, Baker JD, et al. Risk of renal failure after major angiography. Arch Surg. 1983;118:1417–1420
  12. McCullough PA, Wolyn R, Rocher LL, Levin RN, O’Neill WW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med. 1997;103:368–375
  13. Parfrey PS, Griffiths SM, Barrett BJ, et al. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both: a prospective controlled study. N Engl J Med. 1989;320(3):143–149
  14. Schwab SJ, Hlatky MA, Pieper KS, et al. Contrast nephrotoxicity: a randomized controlled trial of a nonionic and an ionic radiographic contrast agent. N Engl J Med. 1989;320(3):149–153
  15. Solomon R, Werner C, Mann D, D’Elia J, Silva P. Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents. N Engl J Med. 1994;331(21):1416–1420
  16. Stevens MA, McCullough PA, Tobin KJ, et al. A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study. J Am Coll Cardiol. 1999;33(2):403–411
  17. Taliercio CP, Vlietstra RE, Ilstrup DM, et al. A randomized comparison of the nephrotoxicity of iopamidol and diatrizoate in high risk patients undergoing cardiac angiography. J Am Coll Cardiol. 1991;17(2):384–390
  18. Tepel M, Van Der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med. 2000;343(3):180–184
  19. Murphy SW, Barrett BJ, Parfrey PS. Contrast nephropathy. J Am Soc Nephrol. 2000;11(1):177–182
  20. Baker CSR, Wragg A, Kumar S, De Palma R, Baker LRI, Knight CJ. A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study. J Am Coll Cardiol. 2003;41(12):2114–2118
  21. Boccalandro F, Amhad M, Smalling RW, Sdringola S. Oral N-acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast. Catheter Cardiovasc Interv. 2003;58:336–341
  22. Kay J, Chow WH, Chan TM, et al. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. JAMA. 2003;289(5):553–557
  23. Tadros GM, Mouhayar EN, Akinwande AO, et al. Prevention of radiocontrast-induced nephropathy with N-acetylcysteine in patients undergoing coronary angiography. J Invasive Cardiol. 2003;15(6):311–314
  24. Oldemeyer JB, Biddle WP, Wurdeman RL, Mooss AN, Cichowski E, Hilleman DE. Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography. Am Heart J. 2003;146(6):23–28
  25. Adamian MG, Moussa I, Mehran R, et al. The role of Mucomyst administration prior to percutaneous interventions on renal function in patients with chronic renal failure. J Am Coll Cardiol. 2002;39(Suppl-March):1A;Abstract No. 1004.I-10
  26. Diaz-Sandoval LJ, Kosowsky BD, Losordo DW. Acetylcysteine to prevent angiography-related renal tissue injury (The APART Trail). Am J Cardiol. 2002;89(3):356–358
  27. Durrham JD, Caputo C, Dokko J, et al. A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int. 2002;62:2202–2207
  28. Shyu K, Cheng J, Kuan P. Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. J Am Coll Cardiol. 2002;40(8):1383–1388
  29. Briguori C, Manganelli F, Scarpato P, et al. Acetylcysteine and contrast agent-associated nephrotoxicity. J Am Coll Cardiol. 2002;40(2):298–303
  30. Vellero A, Cesano G, Pozzato M, et al. [Contrast nephropathy in cardiac procedures: no advantages with prophylactic use of N-acetylcysteine]. Giornale Italiano di Nefrologia. 2002;19(5):529–533
  31. Birck R, Krzossok S, Markowetz F, Schnülle P, van der Woude FJ, Braun C. Acetylcysteine for prevention of contrast nephropathy: meta-analysis. Lancet. 2003;362:598–603
  32. Isenbarger DW, Kent SM, O’Malley PG. Meta-analysis of randomized clinical trials on the usefulness of acetylcysteine for prevention of contrast nephropathy. Am J Cardiol. 2003;92:1454–1458
  33. Bailey SR. Past and present attempts to prevent radiocontrast nephropathy. Rev Cardiovasc Med. 2001;2(Suppl 1):S14–S18
  34. Gruberg L, Mintz GS, Mehran R, et al. The prognostic implications of further renal function deterioration within 48 hours of interventional coronary procedures in patients with pre-existing chronic renal insufficiency. J Am Coll Cardiol. 2000;36(5):1542–1548
  35. Huber W, Jeschke B, Kreymann B, et al. Haemodialysis for the prevention of contrast-induced nephropathy: outcome of 31 patients with severely impaired renal function, comparison with patients at similar risk and review. Invest Radiol. 2002;37(9):471–481
  36. McCullough PA. Why is chronic kidney disease the “spoiler” for cardiovascular outcomes?. J Am Coll Cardiol. 2003;41(5):725–728
  37. Mann JFE, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med. 2001;134(8):629–636
  38. Marenzi G, Bartorelli AL, Lauri G, et al. Continuous veno-venous hemofiltration for the treatment of contrast-induced acute renal failure after percutaneous coronary interventions. Catheter Cardiovasc Interv. 2003;58:59–64
  39. Marenzi G, Marana I, Lauri G, et al. The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. N Engl J Med. 2003;349(14):1333–1340
  40. Nikolsky E, Mehran R. Understanding the consequences of contrast-induced nephropathy. Rev Cardiovasc Med. 2003;4(Suppl 5):S10–S18
  41. Vogt B, Ferrari P, Schonholzer C, et al. Prophylactic hemodialysis after radiocontrast media in patients with renal insufficiency is potentially harmful. Am J Med. 2001;11:692–698

PII: S0147-9563(06)00227-5

doi: 10.1016/j.hrtlng.2006.08.004

Heart & Lung: The Journal of Acute and Critical Care
Volume 36, Issue 3 , Pages 195-204 , May 2007

Article Tools

* Image Usage & Resolution